JP Morgan Maintains Overweight on Repligen, Raises Price Target to $175

Benzinga Newsdesk www.benzinga.com Positive 82.6%

Neg 0% Neu 0% Pos 82.6%

JP Morgan analyst Casey Woodring maintains Repligen (NASDAQ:RGEN) with a Overweight and raises the price target from $165 to $175.